Cargando…

Dysregulated neutrophil function in individuals with alpha-1 antitrypsin deficiency caused by modified membrane cholesterol content.

Detalles Bibliográficos
Autores principales:	Jundi, Bakr, White, Michelle, Lacey, Noreen, McElvaney, Noel G, Reeves, Emer
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Meeting Abstract
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4625408/ http://dx.doi.org/10.1186/1753-6561-9-S7-A7

Ejemplares similares

The impact of alpha-1 antitrypsin augmentation therapy on neutrophil-driven respiratory disease in deficient individuals
por: Dunlea, Danielle M, et al.
Publicado: (2018)

Alpha-1 Antitrypsin Augmentation Inhibits Proteolysis of Neutrophil Membrane Voltage-Gated Proton Channel-1 in Alpha-1 Deficient Individuals
por: Hawkins, Padraig, et al.
Publicado: (2021)

Is There a Therapeutic Role for Selenium in Alpha-1 Antitrypsin Deficiency?
por: Greene, Catherine M., et al.
Publicado: (2013)

C3d Elicits Neutrophil Degranulation and Decreases Endothelial Cell Migration, with Implications for Patients with Alpha-1 Antitrypsin Deficiency
por: Fee, Laura T., et al.
Publicado: (2021)

Gene targeted therapeutics for liver disease in alpha-1 antitrypsin deficiency
por: McLean, Caitriona, et al.
Publicado: (2009)

Alpha 1 antitrypsin to treat lung disease in alpha 1 antitrypsin deficiency: recent developments and clinical implications
por: Chapman, Kenneth R, et al.
Publicado: (2018)

Alpha-1 antitrypsin regulates neutrophil reactive oxygen species production via inhibition of key players of the respiratory burst oxidase system
por: Alfawaz, Bader, et al.
Publicado: (2013)

Activation of complement component 3 is associated with airways disease and pulmonary emphysema in alpha-1 antitrypsin deficiency
por: O'Brien, Michael E, et al.
Publicado: (2020)

5 Year Expression and Neutrophil Defect Repair after Gene Therapy in Alpha-1 Antitrypsin Deficiency
por: Mueller, Christian, et al.
Publicado: (2017)

Diagnosing α(1)-antitrypsin deficiency: how to improve the current algorithm
por: McElvaney, Noel G.
Publicado: (2015)

Alpha-1 proteinase inhibitors for the treatment of alpha-1 antitrypsin deficiency: safety, tolerability, and patient outcomes
por: Chotirmall, Sanjay H, et al.
Publicado: (2015)

The prevalence of liver abnormalities in individuals with ZZ Alpha-1 Antitrypsin deficiency
por: McElvaney, OF, et al.
Publicado: (2015)

Neutrophil Membrane Cholesterol Content is a Key Factor in Cystic Fibrosis Lung Disease
por: White, Michelle M., et al.
Publicado: (2017)

The prevalence of alpha-1 antitrypsin deficiency in Ireland
por: Carroll, Tomás P, et al.
Publicado: (2011)

Alpha-1 antitrypsin for cystic fibrosis complicated by severe cytokinemic COVID-19
por: McElvaney, Oliver J, et al.
Publicado: (2021)

The importance of CFTR expression for neutrophil function in patients with Cystic Fibrosis
por: Jundi, B, et al.
Publicado: (2015)

A Review of Alpha-1 Antitrypsin Binding Partners for Immune Regulation and Potential Therapeutic Application
por: O’Brien, Michael E., et al.
Publicado: (2022)

Physical Activity, Exercise Capacity and Sedentary Behavior in People with Alpha-1 Antitrypsin Deficiency: A Scoping Review
por: O’Shea, Orlagh, et al.
Publicado: (2023)

In vitro and in vivo modulation of NADPH oxidase activity and reactive oxygen species production in human neutrophils by α(1)-antitrypsin
por: Hawkins, Padraig, et al.
Publicado: (2021)

The role of TIM-containing molecules in airway disease and their potential as therapeutic targets
por: Vega-Carrascal, Isabel, et al.
Publicado: (2012)

Impact of COVID-19 in Patients With Severe Alpha-1 Antitrypsin Deficiency: The IMCA1 Study of the EARCO Clinical Research Collaboration
por: Parr, David G., et al.
Publicado: (2022)

Hypertonic Saline in Treatment of Pulmonary Disease in Cystic Fibrosis
por: Reeves, Emer P., et al.
Publicado: (2012)

Targeting IgG Autoantibodies for Improved Cytotoxicity of Bactericidal Permeability Increasing Protein in Cystic Fibrosis
por: McQuillan, Karen, et al.
Publicado: (2020)

The effect of exacerbations on lung density in α(1)-antitrypsin deficiency
por: Strange, Charlie, et al.
Publicado: (2023)

Alpha-1 antitrypsin augmentation therapy decreases miR-199a-5p, miR-598 and miR-320a expression in monocytes via inhibition of NFκB
por: Hassan, Tidi, et al.
Publicado: (2017)

A randomized, double-blind, placebo-controlled trial of intravenous alpha-1 antitrypsin for ARDS secondary to COVID-19
por: McElvaney, Oliver J., et al.
Publicado: (2022)

Altered Degranulation and pH of Neutrophil Phagosomes Impacts Antimicrobial Efficiency in Cystic Fibrosis
por: Hayes, Elaine, et al.
Publicado: (2020)

Animal Models of Cystic Fibrosis Pathology: Phenotypic Parallels and Divergences
por: Lavelle, Gillian M., et al.
Publicado: (2016)

Association of IREB2 and CHRNA3 polymorphisms with airflow obstruction in severe alpha-1 antitrypsin deficiency
por: Kim, Woo Jin, et al.
Publicado: (2012)

The impact of endoplasmic reticulum stress on neutrophil function in alpha 1 antitrypsin deficiency
por: Shaharom, M, et al.
Publicado: (2015)

Alpha 1 Antitrypsin-Deficient Macrophages Have Impaired Efferocytosis of Apoptotic Neutrophils
por: Lee, Jungnam, et al.
Publicado: (2020)

The Involvement of Glycosaminoglycans in Airway Disease Associated with Cystic Fibrosis
por: Reeves, Emer P., et al.
Publicado: (2011)

Mineralization of alpha-1-antitrypsin inclusion bodies in Mmalton alpha-1-antitrypsin deficiency
por: Callea, Francesco, et al.
Publicado: (2018)

Safety of biweekly α(1)-antitrypsin treatment in the RAPID programme
por: Greulich, Timm, et al.
Publicado: (2018)

Dysregulated plasma lipid mediator profiles in critically ill COVID-19 patients
por: Palmas, Francesco, et al.
Publicado: (2021)

Alpha-1 Antitrypsin Deficiency: Does Increased Neutrophil Adhesion Contribute to Lung Damage?
por: Prendecki, Maria, et al.
Publicado: (2022)

Diagnosis and management of α(1)-antitrypsin deficiency in Europe: an expert survey
por: Horváth, Ildikó, et al.
Publicado: (2019)

Gene therapy for alpha 1-antitrypsin deficiency with an oxidant-resistant human alpha 1-antitrypsin
por: Sosulski, Meredith L., et al.
Publicado: (2020)

Alpha-1 Antitrypsin as a Therapeutic Agent for Conditions not Associated with Alpha-1 Antitrypsin Deficiency
por: Wanner, Adam
Publicado: (2015)

The Multifaceted Effects of Alpha1-Antitrypsin on Neutrophil Functions
por: Janciauskiene, Sabina, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_bhs35an6p1oj3bgcq9t4a0ff0d